Tau pathology evolves throughout Alzheimer’s disease, and emerging biomarkers are providing new opportunities to understand, stage, and monitor that progression. This whitepaper explores how p-Tau 205 and p-Tau 212 complement established tau biomarkers to reveal distinct molecular events from early tau dysregulation to neurodegeneration.
Download the whitepaper to learn:
- How p-Tau 205 and p-Tau 212 fit into the tau biomarker landscape
- Applications for disease staging and therapeutic development
- Translational use cases for clinical trials and response monitoring
- How ultra-sensitive Simoa® technology enables detection across CSF, plasma, and serum
Download the Whitepaper
Related Posts
NPTX2: A Synaptic Biomarker of Circuit Integrity, Cognitive Resilience, and Neurodegeneration
Neurology
Advancing Translational Neuroscience with the Simoa Mammalian GFAP Assay
Publication Brief Understanding astrocyte biology is essential for advancing translational neuroscience. GFAP has emerged as a leading biomarker of CNS injury, and Simoa® technology now enables its ultra-sensitive detection directly…
Proteomics in Transition: From Discovery to Diagnostic Relevance
Proteomics is moving beyond broad discovery to deliver real-time, clinically meaningful insights. At the forefront is Quanterix’s Simoa® digital immunoassay technology, enabling ultra-sensitive, reproducible detection of low-abundance biomarkers in areas…
Neurology
Beyond Blood: Expanding Simoa Applications in Urine, Saliva, Sweat, and Tears
Publication Brief The Quanterix Simoa® platform, known for ultrasensitive detection in plasma, serum, and CSF, now delivers the same performance in alternative matrices—urine, saliva, sweat, and tears. This publication brief…
Immunology
Simoa® IL-17A Advantage PLUS: Potential Biomarker Applications in Health and Disease
App Note IL-17A is a potent pro-inflammatory cytokine that plays critical roles in inflammatory responses, host defense against infections, and tissue regeneration. This application note delves into the physiological and…
Neurology
Beyond Blood: Tear Fluid as a Window into Biomarker Discovery
While blood and CSF have long dominated biomarker research, tear fluid is emerging as a scientifically relevant, non-invasive matrix for detecting systemic and neurological biomarkers. Produced by lacrimal glands and…
Neurology
Sweat As A Non-Invasive Matrix for Cytokine Detection Using Simoa®
Inflammatory cytokines like IL-6, IL-10, and TNF-α are central to understanding aging, immune dysregulation, and chronic disease. With eccrine glands distributed across the body, sweat offers a non-invasive, physiologically relevant…
Neurology
Expanding Access to Ultra-Sensitive Biomarker Testing: Urine as a Non-Invasive Matrix for Simoa Assays
Urine as a Non-Invasive Matrix for Ultra-Sensitive Biomarker Detection with Simoa® The Simoa® platform extends its unmatched sensitivity to urine, enabling detection of low-abundance neurological and infectious disease biomarkers in…